■ Therapeutic domains covered: rheumatoid arthritis, haematology (chronic lymphocytic leukaemia, oral treatment of anaemia in patients with chronic kidney disease), neurology (multiple sclerosis, Alzheimer's disease), gynaecology (pre-term labour), cardiology, endocrinology, and dermatology (moderate to severe chronic plaque of psoriasis, moderate to severe atopic dermatitis). ■ Participation of small to large-size firms, including 3 SME.
Shaping European Early Dialogues (SEED)
■ Project sponsored by the European Commission (Call for tender). ■ Consortium of 14 HTA bodies from 10 countries, led by HAS.
Scope
EDs may be requested for a new technology, with supposed added benefit for patients, during the initial phase of clinical development (e.g. end of phase II) to address questions pertaining to relative effectiveness, economic aspects and other areas relevant for relative and cost effectiveness assessment.
EDs are to be: ■ prospective in nature, focusing on development strategies and not a pre-evaluation of available data; ■ limited to one indication; ■ non-binding; ■ confidential; EDs were free of charge for companies.
Continuous Improvement of the ED Procedure (figure 1)
The procedure used for the SEED EDs was derived from the procedure developed and refined during the EUnetHTA EDs. Further improvements were made, based on the results of short surveys conducted after each ED and the experience of parallel EDs with EMA, namely:
EUNETHTA EARLY DIALOGUE FOLLOW-UP WITH THE SEED PROJECT: OBJECTIVES AND METHODS
■ a list of key issues discussed amongst HTA bodies and provided to the company prior to the face-to-face meeting; ■ change in the final outcome of the ED procedure from minutes proposed by industry, reviewed and validated by HTA bodies to consolidated final written answers from HTA bodies to company's questions.
A step-by-step outline of the draft procedure is provided in figures 2 and 3.
A collaborative approach
The multi-HTA EDs activity has been designed to allow fruitful exchanges between HTA bodies: ■ prior to the face-to-face meeting with the company, allowing HTA agencies:
z to determine the need for additional information or clarification of the briefing document to exchange draft positions of each HTA body, z to identify key issues to be transmitted to the company; ■ on the day of the face-to-face meeting with the company: z closed meeting to discuss differences in the positions of the different HTA bodies, reaching convergence when possible, z after the meeting to make conclusions for the ED and proposals for future improvements. A common outcome, comprising detailed written answers from the participating HTA agencies to company's questions with an executive summary from the SEED coordination team.
Involvement of stakeholders: patient representatives, scientific experts, EMA representatives as observers in multi-HTA EDs and partners in EMA/multi-HTA EDs. 
SEED Partners: HAS (France), HVB (Austria), KCE (Belgium), HIQA (Ireland), RER-ASSR and AIFA (Italy), G-BA and IQWiG (Germany), GYEMSZI (Hungary), ZIN (Netherlands), AVALIA-T, ISCIII and AETSA (Spain), NICE (UK).

SEED
Shaping European Early Dialogues
Results
In total, 11 SEED early dialogues (instead of the planned 10): 8 on drugs, 4 of them being parallel EMA-SEED EDs, and 3 on medical devices were conducted from May 2014 to July 2015.
The EDs concerned various therapeutic areas (oncology, cardiology, haematology, pneumology, auto-immune disease, and rheumatology), both rare and non-rare diseases and involved small and large companies.
Main deliverables
■ 11 EDs conducted with 11 reports on the procedural aspects of each ED.
EUNETHTA EARLY DIALOGUE FOLLOW-UP WITH THE SEED PROJECT: RESULTS AND NEXT STEPS
In addition to the procedure used for SEED multi-HTA EDs, the procedure for SEED EMA/ multi-HTA ED pilots also includes: the most suitable representatives regarding the disease area, the stage of the development plan with specific questions for them and specific ad-hoc training offered. ■ Involvement of other stakeholders (e.g. payers). ■ Proper technical and clinical expertise from the HTA participants to be insured. ■ Development (in parallel to the confidential, product-specific approach of EDs) of public guidance on methodological issues for the development of new technologies. ■ Coordination with the definition of the needs for additional evidence generation, notably for the coverage of evidence development schemes for devices and the adaptive pathways initiative in Europe.
SEED and EUnetHTA
■ 24 multi HTA EDs undertaken in total within EUnetHTA and SEED projects:
z 19 on drugs -including 4 EMA/multi-HTA EDs; z 5 on medical devices. ■ All agencies members of SEED consortium are also partners of EUnetHTA. ■ EUnetHTA procedure (amended after the survey) used as a basis for SEED EDs. ■ ED activities planned to continue within the framework of EUnetHTA JA3
(2016-2019) before the establishment of a permanent structure.
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